Investors were hoping for a good quarter from Intuitive Surgical (NASDAQ: ISRG )
, so much so that I'm a little surprised to see such a positive market
reaction to what was largely an in-line quarter and ongoing murkiness in
the market outlook. Strong shipments of the Xi system are encouraging,
as was the better-than-expected procedure growth, but utilization is
still challenging and Johnson & Johnson (NYSE: JNJ ) and Covidien (NYSE: COV ) continue to highlight their own efforts to drive non-robotic minimally invasive procedures with their tools and instruments.
Read more here:
Why the Market Is Wrong About Intuitive Surgical Stock
No comments:
Post a Comment